P2Y receptors in health and disease.

摘要: The purine- and pyrimidine-sensitive P2Y receptors belong to the large group of G-protein-coupled that are target approximately one-third pharmaceutical drugs used in clinic today. It is therefore not unexpected could be useful targets for drug development. This chapter will discuss receptor-based therapies currently used, development possible future developments. platelet inhibitors blocking ADP-receptor P2Y(12) reduce myocardial infarction, stroke, mortality patients with cardiovascular disease. Clopidogrel (Plavix) was many years second most selling world. improved prasugrel, ticagrelor, elinogrel now entering even more pronounced protective effects. UTP-activated P2Y(2) receptor stimulates ciliary movement secretion from epithelial cells. Cystic fibrosis a monogenetic disease where reduced chloride ion results severe lung early death. No specific treatment has been available, but agonist Denufosol shown improve function expected introduced as cystic soon. In preclinical studies, there indications can important diabetes, osteoporosis, cardiovascular, atherosclerotic conclusion, health humans diseases, we expect beneficial targeting future.